| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $144,971,978 ) (Continued on the next page) |
| | 2026 | 2026 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01DK146795 | Adiponectin Signaling in Bladder Function | 000 | 1 | NIH | 4/24/2026 | $739,141 |
| | 2026 | 2026 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | K23AG090744 | Development and Pilot Testing of an Electronic Health Record-based Serious Illness Communication Intervention for Older Adults in the Emergency Department | 001 | 2 | NIH | 9/8/2026 | $191,484 |
| | 2026 | 2026 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01DK142743 | Selective brain-to-gut communication via transcriptionally-defined vagus-to-enteric neuron circuits | 000 | 1 | NIH | 3/18/2026 | $834,911 |
| | 2026 | 2026 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | K99AA032847 | The multi-organ role of NETs in alcohol-induced ACLF | 000 | 1 | NIH | 8/20/2026 | $177,736 |
| | 2026 | 2026 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R21AI196617 | Impact of Diet on Symptomatic Hereditary Alpha-Tryptasemia | 000 | 1 | NIH | 7/15/2026 | $306,533 |
| | 2026 | 2026 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | K22CA288779 | Early detection and interception of cancer using the mutational signature methodology | 000 | 1 | NIH | 8/13/2026 | $191,484 |
| | 2026 | 2026 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R21AI199146 | Development of next generation spectinomycin analogs that evade modifying enzyme-based resistance and show enhanced potency against multidrug-resistant pathogens. | 001 | 1 | NIH | 7/29/2026 | $0 |
| | 2026 | 2026 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | K01AA032055 | Role of Hepatokines in Alcohol-associated Liver Disease | 000 | 2 | NIH | 8/12/2026 | $177,736 |
| | 2026 | 2026 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R21AI199146 | Development of next generation spectinomycin analogs that evade modifying enzyme-based resistance and show enhanced potency against multidrug-resistant pathogens. | 000 | 1 | NIH | 6/30/2026 | $493,865 |
| | 2026 | 2026 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01HL185389 | Cardiac MRI Phenotyping of Coronary Microvascular Dysfunction | 000 | 1 | NIH | 6/12/2026 | $848,141 |
| | 2026 | 2026 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01CA314254 | One-ended Break Repair in Mammalian Cells | 000 | 1 | NIH | 5/11/2026 | $524,110 |
| | 2026 | 2026 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | K08DK149008 | Role of DNAJC22 in Steatotic Liver Disease | 000 | 1 | NIH | 7/14/2026 | $164,484 |
| | 2026 | 2026 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01HL178578 | Serotonergic circuit mechanisms to enhance upper airway tone and respiration in the setting of opioids and sleep-disordered breathing. | 000 | 1 | NIH | 8/5/2026 | $1,738,060 |
| | 2026 | 2026 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01DA067016 | Brain Circuits Mediating Adverse Effects of Fentanyl–Xylazine: Mechanisms and Therapeutic Targets | 000 | 1 | NIH | 8/14/2026 | $508,734 |
| | 2026 | 2026 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | F32GM167172 | Single-Molecule Dissection of Hypomethylation-Driven Genome Instability | 001 | 1 | NIH | 7/23/2026 | $0 |
| | 2026 | 2026 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | F32GM167172 | Single-Molecule Dissection of Hypomethylation-Driven Genome Instability | 000 | 1 | NIH | 7/23/2026 | $79,300 |
| | 2026 | 2026 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | RF1AG096648 | Adverse Effect of Excessive Amyloid Peptides to Brain Lymphatic Function | 000 | 1 | NIH | 7/31/2026 | $3,481,644 |
| | 2026 | 2026 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01NS149672 | Meningeal sensory neuroimmune interactions underlying migraine headache | 000 | 1 | NIH | 7/24/2026 | $749,073 |
| | 2026 | 2026 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | RF1MH144469 | ?DIGITS: DIGital health Interoperability Technology Standards | 000 | 1 | NIH | 8/3/2026 | $2,961,081 |
| | 2026 | 2026 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01HD119808 | Mechanisms and Therapeutic Approaches for Lymphatic Pathology Caused by Dysregulated NFATc1 | 000 | 6 | NIH | 8/27/2026 | $724,852 |
| | 2026 | 2026 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | K08HL181191 | Vascular Piezo1 in Thrombosis | 000 | 1 | NIH | 8/12/2026 | $164,484 |
| | 2026 | 2026 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01AA032953 | Myeloid-derived suppressor cells in alcohol-associated steatohepatitis | 000 | 1 | NIH | 8/26/2026 | $682,736 |
| | 2026 | 2026 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | F32HL186556 | Investigating Inflammatory Pathways in Pulmonary Vascular Disease | 000 | 1 | NIH | 6/25/2026 | $92,476 |
| | 2026 | 2026 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01HL180838 | ADAMTS13 in Human Health and Disease | 000 | 1 | NIH | 6/16/2026 | $1,626,320 |
| | 2026 | 2026 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01HL183196 | Elastin-Like Polypeptide Nanoparticles for Precision Gene Therapy of Cystic Fibrosis | 000 | 1 | NIH | 8/26/2026 | $852,908 |
| | 2026 | 2026 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R21AG103494 | Suburothelial Myofibroblasts Function in Young and Aging Bladder | 000 | 1 | NIH | 7/10/2026 | $475,475 |
| | 2026 | 2026 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | K99HD120622 | Investigating relationships between sexual behavior rhythms, core body temperature, and sleep in female mice: implications for (in)fertility | 000 | 1 | NIH | 8/27/2026 | $129,377 |
| | 2026 | 2026 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01AI202713 | Development of a Novel Trivalent Adjuvanted TB Vaccine | 000 | 1 | NIH | 7/31/2026 | $648,375 |
| | 2026 | 2026 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01AI202713 | Development of a Novel Trivalent Adjuvanted TB Vaccine | 000 | 1 | NIH | 7/31/2026 | $648,375 |
| | 2026 | 2026 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R21NS142800 | SourceSpikeNet – A Biophysically Grounded AI Approach to Spike Detection in EEG | 001 | 1 | NIH | 4/30/2026 | $0 |
| | 2026 | 2026 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R21NS142800 | SourceSpikeNet – A Biophysically Grounded AI Approach to Spike Detection in EEG | 000 | 1 | NIH | 4/21/2026 | $252,060 |
| | 2026 | 2026 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R21AG092912 | Neural mechanisms underlying nocturia-related arousals | 001 | 1 | NIH | 9/18/2026 | $0 |
| | 2026 | 2026 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R21AG092912 | Neural mechanisms underlying nocturia-related arousals | 000 | 1 | NIH | 8/28/2026 | $475,475 |
| | 2026 | 2026 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R35CA294015 | Navigating Pathways of Innate Immunity and Epigenetic Memory in Checkpoint Immunotherapy | 000 | 2 | NIH | 7/27/2026 | $828,758 |
| | 2026 | 2026 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01MD016068 | Effects of DASH Groceries on Blood Pressure in Black Residents of Urban Food Deserts | 000 | 5 | NIH | 4/21/2026 | $831,518 |
| | 2026 | 2026 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | K08HD117001 | Placental NAD and its effect on labor onset | 000 | 2 | NIH | 7/15/2026 | $164,484 |
| | 2026 | 2026 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01DK140239 | Regulation and Requirements for Coenzyme A Biosynthesis | 000 | 2 | NIH | 6/23/2026 | $713,622 |
| | 2026 | 2026 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01HL178894 | Real-World Effectiveness and Value of Glucagon-Like Peptide-1 Receptor Agonists for Prevention of Cardiovascular Disease | 000 | 1 | NIH | 7/14/2026 | $1,725,948 |
| | 2026 | 2026 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01AT013324 | Assessing the Efficacy of Mindfulness Apps | 000 | 1 | NIH | 6/19/2026 | $200,000 |
| | 2026 | 2026 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01AT013324 | Assessing the Efficacy of Mindfulness Apps | 000 | 1 | NIH | 6/19/2026 | $637,845 |
| | 2026 | 2026 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R33CA309703 | Novel Monoclonal Antibody Tools for Exploring the Altered Glycocalyx in Tumor Cells | 000 | 1 | NIH | 3/13/2026 | $430,521 |
| | 2026 | 2026 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01HL173557 | Vascular-targeted Atheroprotective Gene therapies to Prevent Vein Graft Failure | 000 | 3 | NIH | 3/10/2026 | $711,768 |
| | 2026 | 2026 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01HL173557 | Vascular-targeted Atheroprotective Gene therapies to Prevent Vein Graft Failure | 001 | 3 | NIH | 4/23/2026 | $22,476 |
| | 2026 | 2026 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01CA310856 | Overcoming Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer | 000 | 1 | NIH | 7/14/2026 | $681,200 |
| | 2026 | 2026 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01LM014689 | HealthCoach: An LLM-driven chatbot to help patients gain actionable insights from their EHR notes and prepare for the next visit | 000 | 2 | NIH | 8/4/2026 | $391,597 |
| | 2026 | 2026 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01HL180887 | Application of Modern Methods to Predict Risk and Estimate Treatment Effectiveness in Cardiogenic Shock | 000 | 2 | NIH | 8/18/2026 | $765,316 |
| | 2026 | 2026 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | U24HL166784 | 2/2: PREcision VENTilation to attenuate Ventilation-Induced Lung Injury (PREVENT VILI) | 001 | 4 | NIH | 9/10/2026 | $680,174 |
| | 2026 | 2026 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01HL177076 | Unraveling The Mechanism of Heart Failure in Hypertrophic Cardiomyopathy with Exercise CMR | 001 | 2 | NIH | 3/6/2026 | $702,834 |
| | 2026 | 2026 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | K24AT009465 | Mentoring and Patient-Oriented Research in Integrative Medicine | 000 | 8 | NIH | 4/21/2026 | $139,701 |
|
